Literature DB >> 23554050

RNAi-mediated MMP-9 silencing inhibits mouse melanoma cell invasion and migration in vitro and in vivo.

Zhao-Yong Tang1, Yang Liu, Long-Xing Liu, Xiao-Yan Ding, Hong Zhang, Liao-Qiong Fang.   

Abstract

MMP-9 participates in tumour growth, invasion, metastasis and vascularisation. Thus, inhibition of MMP-9 may be involved in the process of tumourigenesis. We have investigated the effect of RNAi-mediated MMP-9 silencing on inhibiting invasion and migration of mouse melanoma cell B16. A specific and optimised siRNA vector was used to target MMP-9 mRNA synthesis in B16 cells. Changes of invasion and migration capability of B16 cell were examined after transfection at different time, and a footpad tumour model was performed to measure the effect of MMP-9 siRNA on melanoma tumourigenesis in vivo. In vitro, down-regulation of MMP-9 expression significantly inhibited B16 cell invasion and migration. In vivo, intratumoural injection of plasmid DNA expressing MMP-9 siRNA every 3 days for three times remarkably inhibited melanoma growth and also suppressed tumour metastasis. The results indicate that RNA-mediated targeting of MMP-9 may have promising applications for the treatment of melanoma.
© 2013 International Federation for Cell Biology.

Entities:  

Keywords:  MMP-9; anti-cancer therapy; invasion; melanoma; metastasis; siRNA; tumour growth

Mesh:

Substances:

Year:  2013        PMID: 23554050     DOI: 10.1002/cbin.10107

Source DB:  PubMed          Journal:  Cell Biol Int        ISSN: 1065-6995            Impact factor:   3.612


  7 in total

1.  The role of mechano-growth factor E peptide in the regulation of osteosarcoma.

Authors:  Jin Shang; Xin Fan; Huan Liu
Journal:  Oncol Lett       Date:  2015-06-09       Impact factor: 2.967

2.  Genetic variants in the metzincin metallopeptidase family genes predict melanoma survival.

Authors:  Yinghui Xu; Yanru Wang; Hongliang Liu; Qiong Shi; Dakai Zhu; Christopher I Amos; Shenying Fang; Jeffrey E Lee; Terry Hyslop; Xin Li; Jiali Han; Qingyi Wei
Journal:  Mol Carcinog       Date:  2017-08-28       Impact factor: 4.784

3.  MMP-9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients With BRAFV600E Mutation Detected in Circulating-Free DNA.

Authors:  Rossella Salemi; Luca Falzone; Gabriele Madonna; Jerry Polesel; Diana Cinà; Domenico Mallardo; Paolo A Ascierto; Massimo Libra; Saverio Candido
Journal:  Front Pharmacol       Date:  2018-08-14       Impact factor: 5.810

Review 4.  MMP9: A Tough Target for Targeted Therapy for Cancer.

Authors:  Katarzyna Augoff; Anita Hryniewicz-Jankowska; Renata Tabola; Kamilla Stach
Journal:  Cancers (Basel)       Date:  2022-04-06       Impact factor: 6.639

5.  Characterization of Vemurafenib-Resistant Melanoma Cell Lines Reveals Novel Hallmarks of Targeted Therapy Resistance.

Authors:  Martina Radić; Ignacija Vlašić; Maja Jazvinšćak Jembrek; Anđela Horvat; Ana Tadijan; Maja Sabol; Marko Dužević; Maja Herak Bosnar; Neda Slade
Journal:  Int J Mol Sci       Date:  2022-08-31       Impact factor: 6.208

6.  Nuclear DLC1 exerts oncogenic function through association with FOXK1 for cooperative activation of MMP9 expression in melanoma.

Authors:  Xintao Yang; Feng Hu; Jessica Aijia Liu; Shan Yu; May Pui Lai Cheung; Xuelai Liu; Irene Oi-Lin Ng; Xin-Yuan Guan; Kelvin K W Wong; Rakesh Sharma; Hong Lok Lung; Yufei Jiao; Leo Tsz On Lee; Martin Cheung
Journal:  Oncogene       Date:  2020-03-25       Impact factor: 9.867

7.  CRISPR-Cas9 Knockdown and Induced Expression of CD133 Reveal Essential Roles in Melanoma Invasion and Metastasis.

Authors:  Cynthia M Simbulan-Rosenthal; Ryan Dougherty; Sahar Vakili; Alexandra M Ferraro; Li-Wei Kuo; Ryyan Alobaidi; Leala Aljehane; Anirudh Gaur; Peter Sykora; Eric Glasgow; Seema Agarwal; Dean S Rosenthal
Journal:  Cancers (Basel)       Date:  2019-10-03       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.